This article features interviews conducted with industry experts Lorenza Rimassa, Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Arndt Vogel, Hannover Medical School, Germany; and Harpreet Wasan, Gastrointestinal Medical Oncology, Imperial College, Hammersmith Hospital, London, UK.
Hailing from different specialities, the experts provided unique insight into cholangiocarcinoma (CCA) diagnosis and treatment. Rimassa highlighted the importance of increasing awareness of CCA to improve diagnosis and reduce disease burden, whilst Vogel and Harpreet discussed the critical nature of appropriate molecular testing to detect FGFR2 fusions.
The experts uniformly agreed that precision medicine holds the key to improving and streamlining the process of molecular testing and that the landscape of CCA treatment is expected to evolve rapidly once the results of several ongoing clinical trials are published.
